Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Bauman J, Verschraegen C, Belinsky S, Muller C, Rutledge T, Fekrazad M, Ravindranathan M, Lee SJ, Jones D. Bauman J, et al. Among authors: verschraegen c. Cancer Chemother Pharmacol. 2012 Feb;69(2):547-54. doi: 10.1007/s00280-011-1729-2. Epub 2011 Sep 8. Cancer Chemother Pharmacol. 2012. PMID: 21901396 Clinical Trial.
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelkà AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ. Vadhan-Raj S, et al. Among authors: verschraegen cf. Ann Intern Med. 2000 Mar 7;132(5):364-8. doi: 10.7326/0003-4819-132-5-200003070-00005. Ann Intern Med. 2000. PMID: 10691586 Clinical Trial.
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH. Verschraegen CF, et al. J Cancer Res Clin Oncol. 2003 Oct;129(10):549-55. doi: 10.1007/s00432-003-0481-3. Epub 2003 Aug 29. J Cancer Res Clin Oncol. 2003. PMID: 14513369 Clinical Trial.
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R. Verschraegen CF, et al. Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. doi: 10.1007/s00280-003-0696-7. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586557 Clinical Trial.
Incidence and survival rates for female malignant germ cell tumors.
Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR. Smith HO, et al. Among authors: verschraegen cf. Obstet Gynecol. 2006 May;107(5):1075-85. doi: 10.1097/01.AOG.0000216004.22588.ce. Obstet Gynecol. 2006. PMID: 16648414
Changing trends in gestational trophoblastic disease.
Smith HO, Wiggins C, Verschraegen CF, Cole LW, Greene HM, Muller CY, Qualls CR. Smith HO, et al. Among authors: verschraegen cf. J Reprod Med. 2006 Oct;51(10):777-84. J Reprod Med. 2006. PMID: 17086806
Absence of epidermal growth factor receptor mutations in cervical cancer.
Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF. Arias-Pulido H, et al. Among authors: verschraegen cf. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54. doi: 10.1111/j.1525-1438.2007.01111.x. Epub 2007 Oct 19. Int J Gynecol Cancer. 2008. PMID: 17949425
Rate of thromboembolic events in mesothelioma.
Nguyen D, Lee SJ, Libby E, Verschraegen C. Nguyen D, et al. Among authors: verschraegen c. Ann Thorac Surg. 2008 Mar;85(3):1032-8. doi: 10.1016/j.athoracsur.2007.11.064. Ann Thorac Surg. 2008. PMID: 18291192
216 results